What to know about Kyle Diamantas, the new acting FDA commissioner

US Food and Drug Commissioner Marty Makary resigned on Tuesday, as announced by President Donald Trump. The departure follows weeks of public speculation and pressure. Kyle Diamantas, the FDA Deputy Commissioner for Food, will serve as acting commissioner. President Trump stated that Makary is a "terrific guy" who will "go on and lead a good life" and that he was experiencing "some difficulty." This leadership change is the latest at the federal health department.

Dr. Marty Makary, the head of the Food and Drug Administration (FDA), is resigning after just over a year in the position. His tenure was marked by complaints from pharmaceutical executives, vaping lobbyists, and anti-abortion groups, as well as internal struggles with FDA staff. Makary, a surgeon and health researcher, gained attention for his criticism of COVID-19 measures. He faced challenges balancing Republican calls to reduce FDA regulations with Health Secretary Robert F. Kennedy Jr.'s interest in scrutinizing product safety. His departure follows a period of significant agency changes and controversies.

Marty Makary has resigned as Commissioner of the US Food and Drug Administration (FDA) after a 13-month tenure marked by significant clashes. Reports indicate his departure follows disagreements with the White House, particularly President Trump, over the approval of fruit-flavored vapes. Makary initially halted their approval but the FDA later announced it would move forward. He also faced criticism from Congress regarding drug regulation and the review of mifepristone. The FDA under Makary reportedly delayed the publication of vaccine safety research and made controversial decisions regarding vaccine approvals, which were sometimes reversed after public outcry. Kyle Diamantas is reported as Makary's acting replacement.